TY - JOUR
T1 - Efficacy of therapy of different variants of anaplastic large T-cell lymphomas
AU - Vinogradova, Yu E.
AU - Lutsenko, I. N.
AU - Kaplanskaya, I. B.
AU - Vorobyev, I. A.
AU - Samoilova, R. S.
AU - Gorgidze, L. A.
AU - Ryzhkova, N. A.
AU - Valiev, T. T.
AU - Gilyazitdinova, E. A.
AU - Dzhulakyan, U. L.
AU - Egorova, E. K.
AU - Zvonkov, E. E.
AU - Krasilnikova, B. B.
AU - Magomedova, A. U.
AU - Margolin, O. V.
AU - Maryin, D. S.
AU - Kremenetskaya, A. M.
AU - Kravchenko, S. K.
AU - Vorobyev, A. I.
PY - 2008/9/11
Y1 - 2008/9/11
N2 - Aim. To compare efficacy of NHL-BFM-90 and CHOP-like courses in the treatment of anaplastic large cell lymphoma (ALCL). Material and methods. Twenty-two patients with ALCL participated in the study. The diagnosis was made basing on the findings of clinical, device, morphological, immunohistochemical and molecular-genetic examinations with application of a panel of monoclonal antibodies to CD30, ALK, CD3, CD4, CD8, CD7, CD34, CD15, CD68, CD20, CD45RO, CD45RA, Ki-67. 14 cases of 22 were negative by kinase of anaplastic lymphocytes (ALK-) and 8 were ppositive (ALK+). Mean age of ALK-ALCL patients was 39.6 ± 4.1 years, of ALK+ALCL patients - 23.4 ± 2.6years. 14 patients were treated by the protocol NHL-BFM-90, 8 were initially treated with other schemes (CHOP, MACOP-B, BEACOPP and others). All 14 patients treated according to NHL-BFM-90 had ALCL stages III-IV with B-symptoms. 12 patients who completed treatment by the above protocol achieved complete remission after the forth course, 2 patients failed the treatment. Of 8 ALCL patients treated initially according to other schemes, a complete remission was achieved in 4 patients (2 had stage II). One of 4 patients with remission had recurrence. Four patients who had failed to achieve complete remission died of the disease progression. Conclusion. ALCL occurs more frequently in young and middle-aged patients. The disease has an aggressive course with rapid generalization. For such processes it is more preferable to use a modified protocol NHL-BFM-90.
AB - Aim. To compare efficacy of NHL-BFM-90 and CHOP-like courses in the treatment of anaplastic large cell lymphoma (ALCL). Material and methods. Twenty-two patients with ALCL participated in the study. The diagnosis was made basing on the findings of clinical, device, morphological, immunohistochemical and molecular-genetic examinations with application of a panel of monoclonal antibodies to CD30, ALK, CD3, CD4, CD8, CD7, CD34, CD15, CD68, CD20, CD45RO, CD45RA, Ki-67. 14 cases of 22 were negative by kinase of anaplastic lymphocytes (ALK-) and 8 were ppositive (ALK+). Mean age of ALK-ALCL patients was 39.6 ± 4.1 years, of ALK+ALCL patients - 23.4 ± 2.6years. 14 patients were treated by the protocol NHL-BFM-90, 8 were initially treated with other schemes (CHOP, MACOP-B, BEACOPP and others). All 14 patients treated according to NHL-BFM-90 had ALCL stages III-IV with B-symptoms. 12 patients who completed treatment by the above protocol achieved complete remission after the forth course, 2 patients failed the treatment. Of 8 ALCL patients treated initially according to other schemes, a complete remission was achieved in 4 patients (2 had stage II). One of 4 patients with remission had recurrence. Four patients who had failed to achieve complete remission died of the disease progression. Conclusion. ALCL occurs more frequently in young and middle-aged patients. The disease has an aggressive course with rapid generalization. For such processes it is more preferable to use a modified protocol NHL-BFM-90.
KW - Anaplastic large cell lymphoma
KW - NHL-BFM-90
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=51149107840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51149107840&partnerID=8YFLogxK
M3 - Article
C2 - 18763592
AN - SCOPUS:51149107840
VL - 80
SP - 33
EP - 37
JO - Terapevticheskii Arkhiv
JF - Terapevticheskii Arkhiv
SN - 0040-3660
IS - 7
ER -